spacer
home > ict > winter 2009 > china: delivering clinical excellence
PUBLICATIONS
International Clinical Trials

China: Delivering Clinical Excellence

OVERVIEW OF THE DRUG MARKET

2008 was one of the busiest years for China with regards to the establishment and revision of drug and medical policies. The pharmaceutical industries again began to thrive after a depression lasting several years. The aggregate amount spent by hospitals on purchasing drugs grew by 32.76 per cent year-on-year in the first half of 2008, four per cent higher than in 2007. The accumulated purchasing amount of medical products over seven classifications amounted to US$28.8 billion during the period of January to July all over the country, which is a yearly growth of 13.15 per cent.

The top 10 drugs used throughout hospitals indicate that anti-tumour drugs, cardiovascular drugs and digestive system drugs have been gaining more and more attention in clinical use.

OVERVIEW OF DRUG APPLICATION SYSTEM OF CHINA

The China State Food and Drug Administration (SFDA) divides chemical drugs into six categories according to world pharmaceutical development status. Those drugs not yet launched onto the market of any country are classified as category 1 or 2, and are regarded as new drugs. Clinical trials from Phase I to Phase III are needed before drugs can be launched, followed by a large sample Phase IV trial conducted soon after they are released onto the market according to regulations. Category 3 to Category 5 are those drugs which are launched in markets other than China, although they are also administrated as new drugs with simplified clinical trial procedures compared to those in Category 1 or 2. Generic drugs are considered to be Category 6. Although products of this category are not new, a Bio-equivalence (BE) study is required before they can be launched onto the market.

Drug development in China runs along the same lines as in other countries, consisting of several steps, including compound screening, preclinical research, clinical trial application, clinical trial, registration application, launch and marketing, and so on. The steps with considerable differences to developed nations are ‘approval system for clinical trial’ and ‘certification system for clinical trial institution’.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Xunting Zeng has decades of experience in the field of clinical trials. Dr Zeng received his PhD at Kansai Medical University, Osaka, Japan, before going on to work as a Special Investigator at the International Medical Center of Japan. Several years later he joined the InCROM Group, a Japanese-based international contract research organisation. Dr Zeng is currently General Manager of InCROM China.

spacer
Dr Xunting Zeng
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Safe’n’Spray™, the smart electronic concept device with child-resistant and locking features, wins the ‘Best Innovation In Drug Delivery Device’ Award at Pharmapack 2020

On February 5th, during the Pharmapack Awards Ceremony, Safe’n’Spray, Nemera’s smart electronic concept device with child-resistant and locking features, was celebrated as the “Best Innovation in Drug Delivery Device”.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement